Clinical trials showed ceritinib works as the second-generation ALK TKI and remains FDA approved for the treatment of metastatic ALK-positive NSCLC patients while displaying potency levels about 20 times stronger than crizotinib. The gene discussed is ALK; the disease is non-small cell lung carcinoma.